Loading organizations...
Saranas is a technology company.
Saranas develops medical devices focused on enhancing patient safety during interventional procedures. Its core technology provides continuous, real-time detection and monitoring of internal bleeding complications, particularly from vascular access during catheterization. This early warning system facilitates prompt clinical intervention, mitigating adverse events and improving patient recovery.
Alex Arevalos and Mehdi Razavi founded Saranas in 2011. They established the company based on their recognition of a critical unmet need: the significant risks of undetected internal bleeding following complex medical interventions. Their expertise led to creating a proactive solution for these post-procedure complications.
Saranas' products serve hospitals and cardiology centers performing high-risk catheter-based procedures with vascular access. Equipping clinicians with essential early detection, the company aims to prevent severe complications and optimize patient outcomes. Saranas envisions a new standard in interventional medicine, ensuring safety and predictability for patients globally.
Saranas has raised $13.0M across 1 funding round.
Saranas has raised $13.0M in total across 1 funding round.
Saranas is a Houston-based medical technology company that develops the Early Bird Bleed Monitoring System (EBBMS), the first FDA-approved device for real-time detection and monitoring of internal bleeding during endovascular procedures.[1][2][3] It serves interventional cardiologists, vascular surgeons, and hospitals performing high-risk interventions like transcatheter aortic valve replacement (TAVR) or mechanical circulatory support (MCS) device placements, addressing the critical problem of undetected bleeding complications that lead to poor patient outcomes and high healthcare costs.[1][3][4] The company has raised $26.28M in funding, achieved Series B stage, and treated over 1,200 patients since its 2019 launch, demonstrating steady clinical adoption.[1][4]
Founded in 2013 in Houston, Texas, Saranas emerged from technology invented at the Texas Heart Institute, focusing on bleed detection for vascular access procedures.[1][3] Key leadership includes President and CEO Zaffer Syed (as of 2019) and more recently Mike MacKinnon, a seasoned medtech executive appointed to drive commercialization.[2][4] Early traction came with FDA de novo classification in 2019 for the EBBMS, followed by 'first-in-human' results presented at the Society for Cardiovascular Angiography Interventions (SCAI), validating its effectiveness in detecting bleeding early.[2] This milestone earned Saranas recognition as one of Houston's most innovative companies that year.[2]
Saranas rides the wave of advancing endovascular interventions, where minimally invasive procedures like TAVR and large-bore device placements are surging due to aging populations and rising cardiovascular disease—yet bleeding remains a top complication (affecting up to 10-20% of cases).[1][3] Timing is ideal post-2019 FDA approval amid growing adoption of structural heart therapies, with market forces like value-based care favoring tools that cut readmissions and costs.[2][4] By enabling immediate intervention, Saranas influences the ecosystem, setting a standard for bleed monitoring and potentially expanding to other high-risk vascular procedures, bolstering Houston's medtech hub status.[2]
Saranas is poised for accelerated commercialization under new CEO Mike MacKinnon, building on 1,200+ patient treatments and Series B funding to scale U.S. adoption and pursue international approvals.[1][4] Trends like AI-enhanced monitoring and expanded structural heart markets will shape its path, potentially driving partnerships with device giants or larger trials for broader indications. Its influence could evolve from niche innovator to standard-of-care provider, directly enhancing endovascular safety and tying back to its core mission of transforming bleed detection in high-stakes procedures.[1][4]
Saranas has raised $13.0M in total across 1 funding round.
Saranas's investors include Baird Capital, General Atlantic, S3 Ventures.
Saranas has raised $13.0M across 1 funding round. Most recently, it raised $13.0M Series B in July 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2021 | $13.0M Series B | Baird Capital, General Atlantic, S3 Ventures |